In this episode, we hear from Megan O'Brien, Associate Director at Access Infinity, to explore why understanding payer perception is so difficult to capture in a structured way.

Megan shares how traditional KPIs like time to access and price only tell part of the story, and why the softer, more subjective elements of payer engagement, from communication frequency to corporate trust, can influence reimbursement outcomes in ways that can be challenging to track. Tune in to hear how primary research and smarter feedback loops could help access teams move from measuring activity to demonstrating real impact.

Send us Fan Mail

Most Favored Nation (MFN) pricing has taken over conversations at conferences, client meetings, and boardrooms alike, but what does it actually mean in practice?

In this episode, we continue the conversation on evolving US pricing policy. Host Louise Bennett is joined by three of the Access Infinity team: Leigh Ann Bruhn, Louisa Byrne, and Richard Mee. Together, they discuss the current MFN landscape from multiple angles: US payer and policy, global pricing and modelling, and ex-US strategic implications.

From the ground at the recent ACCESS Forum in New Orleans, to conversations with European clients, the team explores where MFN stands today, what remains deeply uncertain, and how manufacturers are (and aren't) responding.

A timely conversation for anyone navigating the intersection of US policy and global market access strategy.

To connect and continue the conversation with Leigh Ann, Louisa and Richard, visit the LinkedIn links below:

www.linkedin.com/in/leighannvalue/

www.linkedin.com/in/louisa-oliver-byrne-05a3b212b/

www.linkedin.com/in/richard-mee-3a227a11/

You can also let us know what you thought of this episode by emailing host Louise on louise@accessinfinity.com.

To explore other useful resources on this topic, go to accessinfinity.com/news-resources.

Send us Fan Mail

In this episode we sit down with Nikhil Taxak, Head of Pricing and Market Access Data Analytics at Access Infinity, to explore the rapidly evolving market access landscape.

From the US Most Favored Nation (MFN) policy and Germany's Medical Research Act to surprising developments in Japan's pricing thresholds, Nikhil breaks down how these changes are reshaping pricing and reimbursement strategies worldwide.

The conversation covers emerging regional patterns across Europe, North America, and Asia, with particular focus on three key themes: cost containment measures, value-based innovation recognition, and increasing transparency requirements. Nikhil also addresses the practical challenges pharmaceutical companies face as they navigate stricter evidence requirements, lower price tolerance, and greater global interconnectedness.

This episode references Nikhil's 'In the Loop' email newsletter and 'Navigating the Waves' blog, which he authors with his team. Find out more and subscribe on these links:

https://accessinfinity.com/policy-intelligence/subscribe-to-in-the-loop/

https://accessinfinity.com/news-resources/

and filter 'policy insights'.

Send us Fan Mail